REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Clinical trials for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo trial aims to close cancer care gap for minorities
Disease control Recruiting nowThis early-stage study tests whether giving two targeted drugs together is feasible for people with certain B-cell lymphomas that have returned or stopped responding to prior therapy. The drugs, zanubrutinib and sonrotoclax, work by blocking proteins that help cancer cells surviv…
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 06:45 UTC
-
New combo therapy targets Hard-to-Treat blood cancer
Disease control Recruiting nowThis study tests whether adding a drug called nemtabrutinib to a CAR-T cell therapy (lisocabtagene maraleucel) can better control chronic lymphocytic leukemia (CLL) that has returned or stopped responding to treatment. About 20 adults with relapsed or refractory CLL will receive …
Matched conditions: REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC